Novel synthesis of differentially substituted 5,7-dialkoxyquinazolin-4-ones

Synthetic Communications

Volumn 38, Issue 15, 2008, Pages 2575-2583

  Foote, Kevin M ^a   Hatter, Glenn ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

2 aminobenzonitrile; 5,7 dialkoxyquinazolin 4 ones; 5,7 difluoroquinazolin 4 one; Anthranilic acid

Indexed keywords

7 ETHOXY 5 FLUOROQUINAZOLIN 4 ONE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTUM YIELD; SYNTHESIS;

EID: 51349159661     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397910802219247     Document Type: Article

References (10)

1. Laird, A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin. Invest. Drugs 2003, 12, 51.
2. Bonomi, P. Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert Opin. Invest. Drugs 2003, 12, 1395.
3. Ballard, P.; Bradbury, R. H.; Harris, C. S.; Hennequin, L. F. A.; Hickinson, M.; Johnson, P. D.; Kettle, J. G.; Klinowska, T.; Leach, A. G.; Morgentin, R.; Pass, M.; Ogilvie, D. J.; Olivier, A.; Warin, N.; Williams, E. J. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorg. & Med. Chem. Letters 2006, 16, 1633-1637.
4. Barlaam, B.; Fennell, M.; Germain, H.; Green, T.; Hennequin, L.; Morgentin, R.; Olivier, A.; Plé, P.; Vautier, M.; Costello, G. New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors. Bioorg. & Med. Chem. Letters 2005, 15, 5446-5449.
5. Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Plé, P.; Warin, N.; Costello, G. N-(5-Chloro-1,3- benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4- yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-src/abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465-6488.
6. Barlaam, B. Preparation of quinazolines non-receptor tyrosine kinase inhibitors as antitumor agents. PCT Int. Appl. WO 2004081000.
7. Armarego, W. L. F. An improved preparation of phthalazine and quinazoline. J. Appl. Chem. 1961, 11, 70.
8. AstraZeneca; unpublished results.
9. Roth, G. A.; Tai, J. J. A new synthesis of aryl substituted quinazolin-4(1H)-ones. J. Heterocyclic Chem. 1996, 33, 2051.
10. Fray, M. J.; Mathias, J. P.; Nichols, C. L.; Po-Ba, Y. M.; Snow, H. Synthesis of substituted 2-amino-4-quinazolinones via (ortho-fluorobenzoyl) guanidines. Tetrahedron Letters 2006, 47, 6365-6368.